Langerhans Cell Histiocytosis: Growth Hormone Treatment over 3 years in KIGS Simon J Howell KIGS 10 Year Book, 1999
S J Howell - KIGS 10 Year Book, 1999 Baseline characteristics of 82 KIGS patients with Langerhans cell histiocytosis TSH, thyroid-stimulating hormone; ACTH, adrenocorticotrophic hormone; LH, luteinising hormone; FSH, follicle-stimulating hormone; DI, diabetes insipidus
S J Howell - KIGS 10 Year Book, 1999 Response to GH treatment of patients with LCH (cross-sectional data for 3 years) (1/4)
S J Howell - KIGS 10 Year Book, 1999 Response to GH treatment of patients with LCH (cross-sectional data for 3 years) (2/4)
S J Howell - KIGS 10 Year Book, 1999 Response to GH treatment of patients with LCH (cross-sectional data for 3 years) (3/4)
S J Howell - KIGS 10 Year Book, 1999 Response to GH treatment of patients with LCH (cross-sectional data for 3 years) (4/4)
Response to GH treatment of patients with LCH (longitudinal data for 3 years) S J Howell - KIGS 10 Year Book, 1999 MPH, mid-parental height (1/4)
Response to GH treatment of patients with LCH (longitudinal data for 3 years) S J Howell - KIGS 10 Year Book, 1999 MPH, mid-parental height (2/4)
Response to GH treatment of patients with LCH (longitudinal data for 3 years) S J Howell - KIGS 10 Year Book, 1999 MPH, mid-parental height (3/4)
Response to GH treatment of patients with LCH (longitudinal data for 3 years) S J Howell - KIGS 10 Year Book, 1999 MPH, mid-parental height (4/4)
S J Howell - KIGS 10 Year Book, 1999 Response to GH replacement; comparison of patients with idiopathic GHD and with GHD associated with LCH n/a, not available (Ranke and Guilbaud 1991) (1/3)
S J Howell - KIGS 10 Year Book, 1999 n/a, not available (Ranke and Guilbaud 1991) Response to GH replacement; comparison of patients with idiopathic GHD and with GHD associated with LCH (2/3)
S J Howell - KIGS 10 Year Book, 1999 n/a, not available (Ranke and Guilbaud 1991) Response to GH replacement; comparison of patients with idiopathic GHD and with GHD associated with LCH (3/3)
S J Howell - KIGS 10 Year Book, 1999 a Corresponds to the start of the first year of GH treatment b GH doseand frequency of injections are median values based on the whole of the first year of GH therapy c The range quoted for pubertal patients in the cross-sectional group is the percentage who had entered puberty at the start and at the end of the first year d Data from only 76 patients e Data from only 15 patients Factors influencing first-year height velocity during GH therapy